xalkori 250 mg hard capsules
pfizer limited - crizotinib - hard capsules - 250 mg - carcinoma, non-small-cell lung - anti-neoplastic agents, protein kinase inhibitor - indicated for the treatment of adults with previously treated anaplastic lymphoma kinase (alk)-positive advanced non-small cell lung cancer (nsclc)
xalkori 250mg capsules
pfizer ltd - crizotinib - capsule - 250mg
xalkori 200mg capsules
pfizer ltd - crizotinib - capsule - 200mg
xalkori capsules 200mg
pfizer private limited - crizotinib - capsule - 200 mg - crizotinib 200 mg
xalkori capsules 250mg
pfizer private limited - crizotinib - capsule - 250 mg - crizotinib 250 mg
xalkori 200mg hard capsules
pfizer (malaysia) sdn. bhd. - crizotinib -
xalkori 250mg hard capsules
pfizer (malaysia) sdn. bhd. - crizotinib -
trajentamet 2.5 mg/1000 mg linagliptin 2.5 mg / metformin hydrochloride 1000 mg film-coated tablet blister pack
boehringer ingelheim pty ltd - metformin hydrochloride, quantity: 1000 mg; linagliptin, quantity: 2.5 mg - tablet, film coated - excipient ingredients: copovidone; propylene glycol; magnesium stearate; arginine; iron oxide red; hypromellose; colloidal anhydrous silica; titanium dioxide; maize starch; purified talc - trajentamet is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate, in patients inadequately controlled on metformin alone, or those already being treated and well controlled with the free combination of linagliptin and metformin. trajentamet is indicated in combination with a sulfonylurea (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulfonylurea. trajentamet is indicated in combination with an sglt2 inhibitor (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximum tolerated dose of metformin and an sglt2 inhibitor. trajentamet is indicated as add-on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when insulin and metformin alone do not provide adequate glycaemic control.
trajentamet 2.5 mg/1000 mg linagliptin 2.5 mg / metformin hydrochloride 1000 mg film-coated tablet bottle
boehringer ingelheim pty ltd - metformin hydrochloride, quantity: 1000 mg; linagliptin, quantity: 2.5 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; propylene glycol; maize starch; purified talc; hypromellose; iron oxide red; arginine; magnesium stearate; titanium dioxide; copovidone - trajentamet is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate, in patients inadequately controlled on metformin alone, or those already being treated and well controlled with the free combination of linagliptin and metformin. trajentamet is indicated in combination with a sulfonylurea (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulfonylurea. trajentamet is indicated in combination with an sglt2 inhibitor (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximum tolerated dose of metformin and an sglt2 inhibitor. trajentamet is indicated as add-on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when insulin and metformin alone do not provide adequate glycaemic control.
xalkori 250mg capsulas
pfizer europe ma eeig - crizotinib - crizotinib....250.00 mg